Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Next

Ozlem Tureci, the co-founder of BioNTech, hopes to apply the company's SARS-CoV-2 vaccine success to its initial work developing cancer vaccines, the Associated Press reports.

It adds that, with the pandemic, Tureci and Ugur Sahin, her husband and BioNTech co-founder, switched from working on cancer vaccines to one for SARS-CoV-2. As the AP notes, the Pfizer-BioNTech SARS-CoV-2 vaccine received authorization in the UK and US less than a year later.

"It pays off to make bold decisions and to trust that if you have an extraordinary team, you will be able to solve any problem and obstacle which comes your way in real time," Tureci tells the AP. It adds that among the problems BioNTech faced were conducting large, global clinical trials and ramping up manufacturing.

The AP says BioNTech can use the experience and funds it now has for its cancer vaccine research. Tureci tells it that they have a number of mRNA-based cancer vaccines in the works and expects that they may be able to give them to patients in a few years.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.